ArticleBlood cancer journal2024

The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia.

Cara E Toscan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.